Evidence-based guidelines for the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections were prepared by an Expert Panel of the Infectious Diseases Society of America (IDSA). The guidelines are intended for use by health care providers who care for adult and pediatric patients with MRSA infections. The guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), bacteremia and endocarditis, pneumonia, bone and joint infections, and central nervous system (CNS) infections. Recommendations are provided regarding vancomycin dosing and monitoring, management of infections due to MRSA strains with reduced susceptibility to vancomycin, and vancomycin treatment failures.
EXECUTIVE SUMMARY
MRSA is a significant cause of both health care-associated and community-associated infections. This document constitutes the first guidelines of the IDSA on the treatment of MRSA infections. The primary objective of these guidelines is to provide recommendations on the management of some of the most common clinical syndromes encountered by adult and pediatric clinicians who care for patients with MRSA infections. The guidelines address issues related to the use of vancomycin therapy in the treatment of MRSA infections, including dosing and monitoring, current limitations of susceptibility testing, and the use of alternate therapies for those patients with vancomycin treatment failure and infection due to strains with reduced susceptibility to vancomycin. The guidelines do not discuss active surveillance testing or other MRSA infection-prevention strategies in health care settings, which are addressed in previously published guidelines [1, 2] . Each section of the guidelines begins with a specific clinical question and is followed by numbered recommendations and a summary of the most-relevant evidence in support of the recommendations. Areas of controversy in which data are limited or conflicting and where additional research is needed are indicated throughout the document and are highlighted in the Research Gaps section. The key recommendations are summarized below in the Executive Summary; each topic is discussed in greater detail within the main body of the guidelines.
Please note that specific recommendations on vancomycin dosing and monitoring are not discussed in the sections for each clinical syndrome but are collectively addressed in detail in Section VIII.
I. What is the management of skin and soft-tissue infections (SSTIs) in the era of community-associated MRSA (CA-MRSA)? SSTIs 1. For a cutaneous abscess, incision and drainage is the primary treatment (A-II). For simple abscesses or boils, incision and drainage alone is likely to be adequate, but additional data are needed to further define the role of antibiotics, if any, in this setting.
2. Antibiotic therapy is recommended for abscesses associated with the following conditions: severe or extensive disease (eg, involving multiple sites of infection) or rapid progression in presence of associated cellulitis, signs and symptoms of systemic illness, associated comorbidities or immunosuppression, extremes of age, abscess in an area difficult to drain (eg, face, hand, and genitalia), associated septic phlebitis, and lack of response to incision and drainage alone (A-III).
3. For outpatients with purulent cellulitis (eg, cellulitis associated with purulent drainage or exudate in the absence of a drainable abscess), empirical therapy for CA-MRSA is recommended pending culture results. Empirical therapy for infection due to b-hemolytic streptococci is likely to be unnecessary (A-II). Five to 10 days of therapy is recommended but should be individualized on the basis of the patient's clinical response.
4. For outpatients with nonpurulent cellulitis (eg, cellulitis with no purulent drainage or exudate and no associated abscess), empirical therapy for infection due to b-hemolytic streptococci is recommended (A-II). The role of CA-MRSA is unknown. Empirical coverage for CA-MRSA is recommended in patients who do not respond to b-lactam therapy and may be considered in those with systemic toxicity. Five to 10 days of therapy is recommended but should be individualized on the basis of the patient's clinical response.
5. For empirical coverage of CA-MRSA in outpatients with SSTI, oral antibiotic options include the following: clindamycin (A-II), trimethoprim-sulfamethoxazole (TMP-SMX) (A-II), a tetracycline (doxycycline or minocycline) (A-II), and linezolid (A-II). If coverage for both b-hemolytic streptococci and CA-MRSA is desired, options include the following: clindamycin alone (A-II) or TMP-SMX or a tetracycline in combination with a b-lactam (eg, amoxicillin) (A-II) or linezolid alone (A-II).
6. The use of rifampin as a single agent or as adjunctive therapy for the treatment of SSTI is not recommended (A-III).
7. For hospitalized patients with complicated SSTI (cSSTI; defined as patients with deeper soft-tissue infections, surgical/ traumatic wound infection, major abscesses, cellulitis, and infected ulcers and burns), in addition to surgical debridement and broad-spectrum antibiotics, empirical therapy for MRSA should be considered pending culture data. Options include the following: intravenous (IV) vancomycin (A-I), oral (PO) or IV linezolid 600 mg twice daily (A-I), daptomycin 4 mg/ kg/dose IV once daily (A-I), telavancin 10 mg/kg/dose IV once daily (A-I), and clindamycin 600 mg IV or PO 3 times a day (A-III). A b-lactam antibiotic (eg, cefazolin) may be considered in hospitalized patients with nonpurulent cellulitis with modification to MRSA-active therapy if there is no clinical response (A-II). Seven to 14 days of therapy is recommended but should be individualized on the basis of the patient's clinical response.
8. Cultures from abscesses and other purulent SSTIs are recommended in patients treated with antibiotic therapy, patients with severe local infection or signs of systemic illness, patients who have not responded adequately to initial treatment, and if there is concern for a cluster or outbreak (A-III).
Pediatric considerations
9. For children with minor skin infections (such as impetigo) and secondarily infected skin lesions (such as eczema, ulcers, or lacerations), mupirocin 2% topical ointment can be used (A-III).
10. Tetracyclines should not be used in children ,8 years of age (A-II).
11. In hospitalized children with cSSTI, vancomycin is recommended (A-II). If the patient is stable without ongoing bacteremia or intravascular infection, empirical therapy with clindamycin 10-13 mg/kg/dose IV every 6-8 h (to administer 40 mg/kg/day) is an option if the clindamycin resistance rate is low (eg, ,10%) with transition to oral therapy if the strain is susceptible (A-II). Linezolid 600 mg PO/IV twice daily for children >12 years of age and 10 mg/kg/dose PO/IV every 8 h for children ,12 years of age is an alternative (A-II). ii. Maintain good personal hygiene with regular bathing and cleaning of hands with soap and water or an alcohol-based hand gel, particularly after touching infected skin or an item that has directly contacted a draining wound (A-III).
iii. Avoid reusing or sharing personal items (eg, disposable razors, linens, and towels) that have contacted infected skin (A-III).
13. Environmental hygiene measures should be considered in patients with recurrent SSTI in the household or community setting:
i. Focus cleaning efforts on high-touch surfaces (ie, surfaces that come into frequent contact with people's bare skin each day, such as counters, door knobs, bath tubs, and toilet seats) that may contact bare skin or uncovered infections (C-III).
ii. Commercially available cleaners or detergents appropriate for the surface being cleaned should be used according to label instructions for routine cleaning of surfaces (C-III).
14. Decolonization may be considered in selected cases if: i. A patient develops a recurrent SSTI despite optimizing wound care and hygiene measures (C-III).
ii. Ongoing transmission is occurring among household members or other close contacts despite optimizing wound care and hygiene measures (C-III).
15. Decolonization strategies should be offered in conjunction with ongoing reinforcement of hygiene measures and may include the following:
i. Nasal decolonization with mupirocin twice daily for 5-10 days (C-III).
ii. Nasal decolonization with mupirocin twice daily for 5-10 days and topical body decolonization regimens with a skin antiseptic solution (eg, chlorhexidine) for 5-14 days or dilute bleach baths. (For dilute bleach baths, 1 teaspoon per gallon of water [or ¼ cup per ¼ tub or 13 gallons of water] given for 15 min twice weekly for 3 months can be considered.) (C-III).
16. Oral antimicrobial therapy is recommended for the treatment of active infection only and is not routinely recommended for decolonization (A-III). An oral agent in combination with rifampin, if the strain is susceptible, may be considered for decolonization if infections recur despite above measures (CIII).
17. In cases where household or interpersonal transmission is suspected:
i. Personal and environmental hygiene measures in the patient and contacts are recommended (A-III).
ii. Contacts should be evaluated for evidence of S. aureus infection:
a. Symptomatic contacts should be evaluated and treated (A-III); nasal and topical body decolonization strategies may be considered following treatment of active infection (C-III).
b. Nasal and topical body decolonization of asymptomatic household contacts may be considered (C-III).
18. The role of cultures in the management of patients with recurrent SSTI is limited:
i. Screening cultures prior to decolonization are not routinely recommended if at least 1 of the prior infections was documented as due to MRSA (B-III).
ii. Surveillance cultures following a decolonization regimen are not routinely recommended in the absence of an active infection (B-III).
III. What is the management of MRSA bacteremia and infective endocarditis?
Bacteremia and Infective Endocarditis, Native Valve 19. For adults with uncomplicated bacteremia (defined as patients with positive blood culture results and the following: exclusion of endocarditis; no implanted prostheses; follow-up blood cultures performed on specimens obtained 2-4 days after the initial set that do not grow MRSA; defervescence within 72 h of initiating effective therapy; and no evidence of metastatic sites of infection), vancomycin (A-II) or daptomycin 6 mg/kg/dose IV once daily (AI) for at least 2 weeks. For complicated bacteremia (defined as patients with positive blood culture results who do not meet criteria for uncomplicated bacteremia), 4-6 weeks of therapy is recommended, depending on the extent of infection. Some experts recommend higher dosages of daptomycin at 8-10 mg/kg/dose IV once daily (B-III).
20. For adults with infective endocarditis, IV vancomycin (A-II) or daptomycin 6 mg/kg/dose IV once daily (A-I) for 6 weeks is recommended. Some experts recommend higher dosages of daptomycin at 8-10 mg/kg/dose IV once daily (B-III).
21. Addition of gentamicin to vancomycin is not recommended for bacteremia or native valve infective endocarditis (A-II).
Addition of rifampin to vancomycin is not recommended for bacteremia or native valve infective endocarditis (A-I).
23. A clinical assessment to identify the source and extent of the infection with elimination and/or debridement of other sites of infection should be conducted (A-II).
24. Additional blood cultures 2-4 days after initial positive cultures and as needed thereafter are recommended to document clearance of bacteremia (A-II).
25. Echocardiography is recommended for all adult patients with bacteremia. Transesophageal echocardiography (TEE) is preferred over transthoracic echocardiography (TTE) (A-II).
26. Evaluation for valve replacement surgery is recommended if large vegetation (.10 mm in diameter), occurrence of >1 embolic event during the first 2 weeks of therapy, severe valvular insufficiency, valvular perforation or dehiscence, decompensated heart failure, perivalvular or myocardial abscess, new heart block, or persistent fevers or bacteremia are present (A-II).
Infective Endocarditis, Prosthetic Valve 27. IV vancomycin plus rifampin 300 mg PO/IV every 8 h for at least 6 weeks plus gentamicin 1 mg/kg/dose IV every 8 h for 2 weeks (B-III).
28. Early evaluation for valve replacement surgery is recommended (A-II). 34. In patients with MRSA pneumonia complicated by empyema, antimicrobial therapy against MRSA should be used in conjunction with drainage procedures (A-III).
Pediatric considerations

In children, IV vancomycin is recommended (A-II).
If the patient is stable without ongoing bacteremia or intravascular infection, clindamycin 10-13 mg/kg/dose IV every 6-8 h (to administer 40 mg/kg/day) can be used as empirical therapy if the clindamycin resistance rate is low (eg, ,10%) with transition to oral therapy if the strain is susceptible (A-II). Linezolid 600 mg PO/IV twice daily for children >12 years of age and 10 mg/kg/dose every 8 h for children ,12 years of age is an alternative (A-II).
V. What is the management of MRSA bone and joint infections?
Osteomyelitis 36. Surgical debridement and drainage of associated softtissue abscesses is the mainstay of therapy and should be performed whenever feasible (A-II).
37. The optimal route of administration of antibiotic therapy has not been established. Parenteral, oral, or initial parenteral therapy followed by oral therapy may be used depending on individual patient circumstances (A-III).
38. Antibiotics available for parenteral administration include IV vancomycin (B-II) and daptomycin 6 mg/kg/dose IV once daily (B-II). Some antibiotic options with parenteral and oral routes of administration include the following: TMP-SMX 4 mg/kg/dose (TMP component) twice daily in combination with rifampin 600 mg once daily (B-II), linezolid 600 mg twice daily (B-II), and clindamycin 600 mg every 8 h (B-III).
39. Some experts recommend the addition of rifampin 600 mg daily or 300-450 mg PO twice daily to the antibiotic chosen above (B-III). For patients with concurrent bacteremia, rifampin should be added after clearance of bacteremia.
40. The optimal duration of therapy for MRSA osteomyelitis is unknown. A minimum 8-week course is recommended (A-II). Some experts suggest an additional 1-3 months (and possibly longer for chronic infection or if debridement is not performed) of oral rifampin-based combination therapy with TMP-SMX, doxycycline-minocycline, clindamycin, or a fluoroquinolone, chosen on the basis of susceptibilities (C-III).
41. Magnetic resonance imaging (MRI) with gadolinium is the imaging modality of choice, particularly for detection of early osteomyelitis and associated soft-tissue disease (A-II). Erythrocyte sedimentation rate (ESR) and/or C-reactive protein (CRP) level may be helpful to guide response to therapy (B-III).
Septic Arthritis
Drainage or debridement of the joint space should always be performed (A-II).
For septic arthritis, refer to antibiotic choices for osteomyelitis (recommendation 37 above). A 3-4-week course of therapy is suggested (A-III).
Device-related osteoarticular infections 44. For early-onset (,2 months after surgery) or acute hematogenous prosthetic joint infections involving a stable implant with short duration (<3 weeks) of symptoms and debridement (but device retention), initiate parenteral therapy (refer to antibiotic recommendations for osteomyelitis) plus rifampin 600 mg daily or 300-450 mg PO twice daily for 2 weeks followed by rifampin plus a fluoroquinolone, TMP-SMX, a tetracycline or clindamycin for 3 or 6 months for hips and knees, respectively (A-II). Prompt debridement with device removal whenever feasible is recommended for unstable implants, late-onset infections, or in those with long duration (.3 weeks) of symptoms (A-II).
45. For early-onset spinal implant infections (<30 days after surgery) or implants in an actively infected site, initial parenteral therapy plus rifampin followed by prolonged oral therapy is recommended (B-II). The optimal duration of parenteral and oral therapy is unclear; the latter should be continued until spine fusion has occurred (B-II). For late-onset infections (.30 days after implant placement), device removal whenever feasible is recommended (B-II).
46. Long-term oral suppressive antibiotics (eg, TMP-SMX, a tetracycline, a fluoroquinolone [which should be given in conjunction with rifampin due to the potential emergence of fluoroquinolone resistance, particularly if adequate surgical debridement is not possible should be given in conjunction with rifampin], or clindamycin) with or without rifampin may be considered in selected cases, particularly if device removal not possible (B-III).
Pediatric considerations
47. For children with acute hematogenous MRSA osteomyelitis and septic arthritis, IV vancomycin is recommended (A-II). If the patient is stable without ongoing bacteremia or intravascular infection, clindamycin 10-13 mg/kg/dose IV every 6-8 h (to administer 40 mg/kg/day) can be used as empirical therapy if the clindamycin resistance rate is low (eg, ,10%) with transition to oral therapy if the strain is susceptible (A-II) . The exact duration of therapy should be individualized, but typically a minimum 3-4-week course is recommended for septic arthritis and a 4-6-week course is recommended for osteomyelitis.
48. Alternatives to vancomycin and clindamycin include the following: daptomycin 6 mg/kg/day IV once daily (C-III) or linezolid 600 mg PO/IV twice daily for children >12 years of age and 10 mg/kg/dose every 8 h for children ,12 years of age (C-III).
VI. What is the management of MRSA infections of the CNS?
Meningitis
IV vancomycin for 2 weeks is recommended (B-II).
Some experts recommend the addition of rifampin 600 mg daily or 300-450 mg twice daily (B-III).
50. Alternatives include the following: linezolid 600 mg PO/IV twice daily (B-II) or TMP-SMX 5 mg/kg/dose IV every 8-12 h (C-III).
51. For CNS shunt infection, shunt removal is recommended, and it should not be replaced until cerebrospinal fluid (CSF) cultures are repeatedly negative (A-II).
Brain abscess, subdural empyema, spinal epidural abscess 52. Neurosurgical evaluation for incision and drainage is recommended (A-II) .
53. IV vancomycin for 4-6 weeks is recommended (B-II). Some experts recommend the addition of rifampin 600 mg daily or 300-450 mg twice daily (B-III). 54. Alternatives include the following: linezolid 600 mg PO/IV twice daily (B-II) and TMP-SMX 5 mg/kg/dose IV every 8-12 h (C-III).
Septic Thrombosis of Cavernous or Dural Venous Sinus
Surgical evaluation for incision and drainage of contiguous sites of infection or abscess is recommended whenever possible (A-II). The role of anticoagulation is controversial. 56. IV vancomycin for 4-6 weeks is recommended (B-II).
Some experts recommend the addition of rifampin 600 mg daily or 300-450 mg twice daily (B-III). 57. Alternatives include the following: linezolid 600 mg PO/IV twice daily (B-II) and TMP-SMX 5 mg/kg/dose IV every 8-12 h (C-III).
Pediatric considerations
IV vancomycin is recommended (A-II).
VII. What is the role of adjunctive therapies for the treatment of MRSA infections?
59. Protein synthesis inhibitors (eg, clindamycin and linezolid) and intravenous immunoglobulin (IVIG) are not routinely recommended as adjunctive therapy for the management of invasive MRSA disease (A-III). Some experts may consider these agents in selected scenarios (eg, necrotizing pneumonia or severe sepsis) (C-III).
VIII. What are the recommendations for vancomycin dosing and monitoring?
These recommendations are based on a consensus statement of the American Society of Health-System Pharmacists, the IDSA, and The Society of Infectious Diseases Pharmacists on guidelines for vancomycin dosing [3, 4] . 68. The efficacy and safety of targeting trough concentrations of 15-20 lg/mL in children requires additional study but should be considered in those with serious infections, such as bacteremia, infective endocarditis, osteomyelitis, meningitis, pneumonia, and severe SSTI (ie, necrotizing fasciitis) (B-III). (A-III) .
72. High-dose daptomycin (10 mg/kg/day), if the isolate is susceptible, in combination with another agent (e.g. gentamicin 1 mg/kg IV every 8 h, rifampin 600 mg PO/IV daily or 300-450 mg PO/IV twice daily, linezolid 600 mg PO/IV BID, TMP-SMX 5 mg/kg IV twice daily, or a beta-lactam antibiotic) should be considered (B-III).
73. If reduced susceptibility to vancomycin and daptomycin are present, options may include the following: quinupristindalfopristin 7.5 mg/kg/dose IV every 8 h, TMP-SMX 5 mg/kg/ dose IV twice daily, linezolid 600 mg PO/IV twice daily, or telavancin 10 mg/kg/dose IV once daily (C-III). These options may be given as a single agent or in combination with other antibiotics.
XI. What is the management of MRSA infections in neonates?
Neonatal pustulosis 74. For mild cases with localized disease, topical treatment with mupirocin may be adequate in full-term neonates and young infants (A-III).
75. For localized disease in a premature or very lowbirthweight infant or more-extensive disease involving multiple sites in full-term infants, IV vancomycin or clindamycin is recommended, at least initially, until bacteremia is excluded (A-II).
Neonatal MRSA sepsis 76. IV vancomycin is recommended, dosing as outlined in the Red Book (A-II) [160] .
77. Clindamycin and linezolid are alternatives for nonendovascular infections (B-II).
The prevalence of MRSA has steadily increased since the first clinical isolate was described in 1961, with an estimated 94,360 cases of invasive MRSA disease in the United States in 2005 [5] .
Initially almost exclusively health care-associated, by the mid1990s, MRSA strains were reported as causing infections among previously healthy individuals in the community who lacked health care-associated risk factors [6] . Unlike HA-MRSA, these so-called CA-MRSA isolates are susceptible to many non-ß-lactam antibiotics. Furthermore, they are genetically distinct from HA-MRSA isolates and contain a novel cassette element, SCCmec IV and exotoxin, Panton-Valentine leukocidin (PVL). The epidemiology of MRSA has become increasingly complex as CA-MRSA and HA-MRSA strains have co-mingled both in the community and in health care facilities [7, 8] . Not unexpectedly, MRSA disease has had an enormous clinical and economic impact [9, 10] .
The wide spectrum of illness caused by MRSA includes SSTIs, bacteremia and endocarditis, pneumonia, bone and joint infections, CNS disease, and toxic shock and sepsis syndromes. CA-MRSA was the most common cause of SSTI in a geographically diverse network of emergency departments in the United States [11] ; however, there may be differences in local epidemiology to consider when implementing these guidelines. SSTIs may range in clinical presentation from a simple abscess or cellulitis to deeper soft-tissue infections, such as pyomyositis, necrotizing fasciitis, and mediastinitis as a complication of retropharyngeal abscess [12] [13] [14] [15] . Bacteremia accompanies the majority (75%) of cases of invasive MRSA disease [5] . A multitude of disease manifestations have been described, including, but not limited to, infective endocarditis; myocardial, perinephric, hepatic, and splenic abscesses; septic thrombophlebitis with and without pulmonary emboli [16] ; necrotizing pneumonia [17] [18] [19] [20] [21] ; osteomyelitis complicated by subperiosteal abscesses; venous thrombosis and sustained bacteremia [16, 22, 23] ; severe ocular infections, including endophthalmitis [24] ; sepsis with purpura fulminans [25] ; and Waterhouse-Friderichsen syndrome [26] .
The 
